About MannKind

MannKind Corporation (Nasdaq: MNKD) focuses on the discovery, development and commercialization of therapeutic products for patients with diseases such as diabetes.

In addition, MannKind is applying our novel technologies and services to support partner development efforts. More >

 
Worldwide rights to AFREZZA have been licensed to Sanofi. For more information about AFREZZA, please visit www.Afrezza.com.

Spotlight

Sanofi and MannKind  Announce Global Licensing Agreement for Afrezza® (insulin human) Rapid-Acting Inhaled Insulin 
More >

News & Events

   
Jan 12, 2015 MannKind CEO Alfred Mann to Transition to Executive Chairman; COO and President Hakan... More >
Jan 08, 2015 MannKind Earns $50 Million in Milestone Payments From Sanofi More >
Jan 07, 2015 MannKind Corporation to Present at the J.P. Morgan 2015 Healthcare Conference More >